Bank of New York Mellon Corp Sells 14,912 Shares of Biohaven Ltd. (NYSE:BHVN)

Bank of New York Mellon Corp cut its holdings in shares of Biohaven Ltd. (NYSE:BHVN – Get Rating) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,000,497 shares of the company’s stock after selling 14,912 shares during the period. Bank of New York Mellon Corp owned about 1.47% of Biohaven worth $151,244,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. JBF Capital Inc. acquired a new position in Biohaven during the 3rd quarter worth $63,000. US Bancorp DE lifted its holdings in Biohaven by 19.1% during the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after buying an additional 94 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in Biohaven by 42.1% during the 2nd quarter. Lazard Asset Management LLC now owns 1,243 shares of the company’s stock worth $181,000 after buying an additional 368 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in Biohaven during the 1st quarter worth $200,000. Finally, Virtu Financial LLC acquired a new position in Biohaven during the 2nd quarter worth $207,000. 98.01% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. started coverage on Biohaven in a research note on Wednesday, January 4th. They issued an “overweight” rating and a $23.00 price target on the stock. SVB Leerink reissued an “outperform” rating and issued a $24.00 target price on shares of Biohaven in a research note on Tuesday, January 24th. BTIG Research assumed coverage on Biohaven in a research note on Friday, December 2nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, SVB Securities assumed coverage on Biohaven in a research note on Tuesday, January 24th. They issued an “outperform” rating and a $24.00 target price on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Biohaven presently has a consensus rating of “Moderate Buy” and an average price target of $48.75.

Biohaven Price Performance

NYSE BHVN opened at $13.77 on Friday. The firm has a market cap of $938.58 million, a P/E ratio of -0.99 and a beta of 1.12. The stock’s 50-day moving average is $16.57 and its 200-day moving average is $38.76. Biohaven Ltd. has a one year low of $5.54 and a one year high of $20.57.

About Biohaven

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.